Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease. Objective: To evaluate the dual ChE inhibitor, rivastigmine, in more severe dementia. Methods: We retrospectively analysed pooled data from three randomised, placebo‐controlled, double‐blind, 6‐month trials, involving 2126 AD subjects. Subjects were selected according to baseline Mini‐Mental State Examination (MMSE) score to identify subjects with more severe cognitive impairment (10–12 MMSE points). One‐hundred‐and‐seventeen subjects were included who had been treated with rivastigmine 6–12 mg/day or placebo. The AD Assessment Scale‐Cognitive Subscale (ADAS‐Cog), the MMSE, a six‐item subscore of the Progressive Deterioration Scale (PDS) and the BEHAVE‐AD assessed efficacy. Tolerability was assessed by recording adverse events (AEs) and the relative risk (RR) of discontinuation. Results: This group of subjects responded well to rivastigmine. After 6 months, the mean ADAS‐Cog score declined by 6.3 points in the placebo group and increased by 0.2 points in the rivastigmine group (observed cases; p<0.001). Clinical benefits were also observed with the MMSE, the six‐item PDS score and items of the BEHAVE‐AD. Rivastigmine showed the same pattern of AEs as in other studies, but the RR of dropping out due to AEs was lower than in subjects with milder AD. Conclusion: Current treatment guidelines do not recommend treating individuals with severe AD with ChE inhibitors. However, this retrospective analysis suggests that rivastigmine 6–12 mg/day may benefit subjects with more severe disease, as well as subjects with mild to moderate impairment. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Self-citationRosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314 · cited 5×
“This may be of interest within the context of severe disease because studies have indicated that AChE activity decreases as the disease develops, while BuChE activity remains unchanged or increases (Perry et al., 1978; Arendt et al., 1992).”
BackgroundInfluentialBehavioral Pathology in Alzheimer’s Disease (BEHAVE-AD) Rating Scale
Reisberg, B., Auer, S. R., & Monteiro, I. M. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297003529 · Cited by 209 · cited 1×
“Behavioural changes were evaluated using the BEHAVEAD scale, which has 25 items in seven groups covering paranoid and delusional ideation, hallucinations, activity disturbances, aggressiveness, diurnal rhythm disturbances, affective disturbances and anxieties/ phobias (Reisberg et al., 1996).”
MethodTrinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Cited by
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Rivastigmine for Alzheimer's disease
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub2 · Cited by 296
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Metadata
- Authors
- Burns, A., Spiegel, R., & Quarg, P.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2004-02-16
- Volume
- 19
- Issue
- 3
- Pages
- 243-249
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2037468903
- Cited by
- 65
- References
- 5
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. https://app.cochat.ai/papers/10.1002/gps.1058
- The paper
- Burns, A., Spiegel, R., & Quarg, P. (2004). Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.1058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.